Kopran Ltd
Kopran Ltd Q1 FY26 Results & Presentation Highlights: Revenue, Margins & Order Book
Q1 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Kopran Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1 FY 2025-26 revenue from operations: Rs. Q1 FY 2025-26 EBITDA: Rs.
From Kopran Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 FY 2025-26 revenue from operations: Rs. 13,522 Lakhs (Page 5)
- Q1 FY 2024-25 revenue: Rs. 13,944 Lakhs (Page 5)
- Year-on-year change in revenue: Slight decrease (Rs. 13,522 Lakhs vs Rs. 13,944 Lakhs)
- Formulations Q1 FY 2025-26 revenue: Rs. 5,078 Lakhs; FY 2024-25 revenue: Rs. 26,249 Lakhs (Page 10)
- APIs Q1 FY 2025-26 revenue: Rs. 8,303 Lakhs; FY 2024-25 revenue: Rs. 35,881 Lakhs (Page 8)
- Total sales/other income FY 2024-25: Rs. 63,359 Lakhs (Page 20)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Kopran Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Strategic imperatives (Page 15) mention capacity expansion and setting up an API and R&D facility at Panoli.
- No specific amount for capex is detailed in the presentation.
- The focus is on capacity expansion to develop niche, high-value/high-volume APIs and intermediates.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Kopran Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹234 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Kopran Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- NGL Fine Chem Ltd (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key investor presentation takeaways from NGL Fine Chem Ltd's Q1 FY26 investor presentation — and how it ranks a
- Influx Healthtech Ltd (Q1 FY26)
FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). Key investor presentation takeaways from Influx Healthtech Ltd'
- Shree Ganesh Remedies Ltd (Q1 FY26)
Q1FY26 Revenue from Operations: ₹24.67 crores . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q1 FY26 investor presentation — and how it
- Anuh Pharma Ltd (Q1 FY26)
Operating Revenue for Q1 FY 2026: ₹186.48 Cr, a 35.22% increase year-on-year from ₹137.91 Cr in Q1 FY 2025. Key investor presentation takeaways from Anuh Pharma
Frequently Asked Questions
What were Kopran Ltd Q1 FY26 results?
Q1 FY 2025-26 revenue from operations: Rs. Q1 FY 2025-26 EBITDA: Rs.
What is Kopran Ltd share price analysis?
Kopran Ltd currently shows a neutral. The stock trades at a P/E of 53.7 with a market cap of ₹1,342 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kopran Ltd planning capital expenditure?
Strategic imperatives (Page 15) mention capacity expansion and setting up an API and R&D facility at Panoli.
Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.